Oct. 21, 2019 — What is next in the effort to require inclusion of list prices in direct-to-consumer (DTC) promotion of pharmaceuticals? A variety of scenarios were outlined by James Czaban, chair of the FDA Practice Group at DLA Piper in Washington, during a panel at last week’s Food and Drug Law Institute conference on […]
Read more
Jan. 3, 2019 – As healthcare communicators start off 2019, keeping an eye on the best ways to remain compliant is now a bit easier thanks to James N. Czaban, chair of the FDA and Medical Products Regulatory Practice at DLA Piper LLP in Washington, D.C. Speaking at the Coalition for Healthcare Communication’s Post-election Conference […]
Read more